Patients with gastrinomas that are also known to be part of neuroendocrine neoplasms must have to deal with two factors related to this tumor. First, controlling the high amounts by using medications that inhibit gastrin levels. The second part is stabilizing the tumor progression. Gastrinomas have a rate of 60–90% that will become malignant. Patients who do not seek medical treatment such anti-ulcer medication have high rate of recurrence and death secondary to ulcer disease. The prognosis of gastrinoma depends on the level of metastases of the tumor. If patients present with hepatic metastases they might have remaining life span of 1 year with a 5-year survival rate of 20–30%. In patients with localized tumor or localized lymph spread the survival rate of 5 years is 90%. Lastly, surgical resection of local tumor could lead to complete cure without recurrence in 20–25% of patients.
causes of Zollinger–Ellison syndrome
risks of Peritonitis
risks of Short bowel syndrome
risks of Giardiasis
causes of Peanut allergy
causes of Gerstmann syndrome
causes of Heartburn
risks of Stevens–Johnson syndrome